Indications and uses
for temporary relief of symptoms commonly associated with herpes simplex virus such as: • itching • stinging • tingling • swelling
for temporary relief of symptoms commonly associated with herpes simplex virus such as: • itching • stinging • tingling • swelling
Dispense Viratrol directly into mouth, or add recommended dosage into 8-12 oz. of purified (non-chlorinated) water and drink. Safe for ages 2 and up.
do not use if tamper seal is broken store in a cool, dry place product msut not come in contact with metal do not store next to electrical devices or appliance
Apis mellifica
Arsenicum album
Borax
Capsicum annuum
Graphites
Mentha piperita
Mezereum
Natrum muriaticum
Nux vomica
Petroleum
Ranunculus bulbosus
Rhus toxicodendron
Each ingredient contains equal volumes of 10X, 30X and 100X potencies.
The letters “HPUS” indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States.
Product indications are based on Homeopathic Materia Medica.
Apis mellifica....................................Tingling
Arsenicum album ..............................Swelling
Borax.………………............................Itching
Capsicum annuum.............................Skin eruptions
Graphites..........................................Stinging
Mentha piperita............…..................Sensitive skin
Mezereum.........................................Burning
Natrum muriaticum....…………………..Fever blisters
Nux vomica……………………………..Burning
Petroleum..……………………….…….Sores
Ranunculus bulbosus.........………….Minor eruptions of cold sores
Rhus toxicodendron ….…………..….Redness
for temporary relief of symptoms commonly associated with herpes simplex virus
such as:
• itching
• stinging
• tingling
• swelling
Stop use and ask a doctor, if symptoms persist or worsen.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of the reach of children.
Dispense Viratrol directly into mouth, or add recommended dosage into 8-12 oz. of purified (non-chlorinated) water and drink. Safe for ages 2 and up.
30-50 lbs 1/2 mL
(13.6-22.6 kg) twice per day
50+ lbs 1 mL
(22.6+ kg) twice per day
External Use: if needed, apply to affected areas 2-6 times daily until symptoms improve.
citric acid, potassium sorbate, purified ionized mineral water
You can email us at
info@hellolife.net or call us
toll-free at
1.800.875.0850. Monday through Friday,
9am-5pm ET.
www.hellolife.net
Mftd for: HelloLife, LLC 4460 44th St.
SE Ste. C-600 Grand Rapids, MI 49512
FDA Pharmaceutical Establishment
#1053442, #3009727070
www.viratrol.com
NDC 49726-009-02
Viratrol TM
Herpes Symptom Relief
For the temporary relief of symptoms commonly associated with herpes simplex virus, such as:
2 fl oz (59 mL)
Homeopathic (OTC) Medicine
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49726-009-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-cc31-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49726-009-02 | ViratrolHerpes Symptom Relief | 59 mL in 1 BOTTLE | LIQUID | 59 | 8 | |
| 49726-009-02 | ViratrolHerpes Symptom Relief | 1 in 1 CARTON | LIQUID | 1 | 8 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 49726-009 | VIRATROL HERPES SYMPTOM RELIEF (APIS MELLIFICA, ARSENICUM ALBUM, BORAX, CAPSICUM ANNUUM, GRAPHITES, MENTHA PIPERITA, MEZEREUM, NATRUM MURIATICUM, NUX VOMICA, PETROLEUM, RANUNCULUS BULBOSUS) LIQUID [HELLO LIFE, INC.] | 8 | Legacy NDC, 2 package rows | 20181227_babcbe50-05c2-45d7-a1f5-07f65bbb45e8.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| APIS MELLIFERA | ACTIVE INGREDIENT | 7S82P3R43Z | 4 | |
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 4 | |
| CAPSICUM | ACTIVE INGREDIENT | 00UK7646FG | 4 | |
| DAPHNE MEZEREUM BARK | ACTIVE INGREDIENT | X2N6E405GV | 4 | |
| GRAPHITE | ACTIVE INGREDIENT | 4QQN74LH4O | 4 | |
| PARAFFIN | ACTIVE INGREDIENT | I9O0E3H2ZE | 4 | |
| PEPPERMINT | ACTIVE INGREDIENT | V95R5KMY2B | 4 | |
| RANUNCULUS BULBOSUS | ACTIVE INGREDIENT | AEQ8NXJ0MB | 4 | |
| SODIUM BORATE | ACTIVE INGREDIENT | 91MBZ8H3QO | 4 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 4 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE INGREDIENT | 269XH13919 | 4 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 4 | |
| APIS MELLIFERA | ACTIVE MOIETY | 7S82P3R43Z | 4 | |
| ARSENIC CATION (3+) | ACTIVE MOIETY | C96613F5AV | 4 | |
| BORATE ION | ACTIVE MOIETY | 44OAE30D22 | 4 | |
| CAPSICUM | ACTIVE MOIETY | 00UK7646FG | 4 | |
| CHLORIDE ION | ACTIVE MOIETY | Q32ZN48698 | 4 | |
| DAPHNE MEZEREUM BARK | ACTIVE MOIETY | X2N6E405GV | 4 | |
| GRAPHITE | ACTIVE MOIETY | 4QQN74LH4O | 4 | |
| PARAFFIN | ACTIVE MOIETY | I9O0E3H2ZE | 4 | |
| PEPPERMINT | ACTIVE MOIETY | V95R5KMY2B | 4 | |
| RANUNCULUS BULBOSUS | ACTIVE MOIETY | AEQ8NXJ0MB | 4 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE MOIETY | 269XH13919 | 4 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 4 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 4 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49726-009 | 49726-009-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| POTASSIUM SORBATE | 1VPU26JZZ4 | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| APIS MELLIFERA | 7S82P3R43Z | ACTIB |
| ARSENIC TRIOXIDE | S7V92P67HO | ACTIB |
| SODIUM BORATE | 91MBZ8H3QO | ACTIB |
| CAPSICUM | 00UK7646FG | ACTIB |
| GRAPHITE | 4QQN74LH4O | ACTIB |
| PEPPERMINT | V95R5KMY2B | ACTIB |
| DAPHNE MEZEREUM BARK | X2N6E405GV | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | ACTIB |
| STRYCHNOS NUX-VOMICA SEED | 269XH13919 | ACTIB |
| PARAFFIN | I9O0E3H2ZE | ACTIB |
| RANUNCULUS BULBOSUS | AEQ8NXJ0MB | ACTIB |
| TOXICODENDRON PUBESCENS LEAF | 6IO182RP7A | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | EMULSION / OPHTHALMIC | 0.47 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | ELIXIR / ORAL | 100 mg/5ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / AURICULAR (OTIC) | 0.2 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / RECTAL | 6.67 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / ORAL | 446 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / AURICULAR (OTIC) | 0.04 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO, SUSPENSION / TOPICAL | 0.25 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, CHEWABLE / ORAL | 7 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | AEROSOL, FOAM / TOPICAL | 8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / IRRIGATION | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / PERIDURAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRASYNOVIAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRA-ARTICULAR | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / ORAL | 114 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY / NASAL | 9 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / VAGINAL | 0.49 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING / ORAL | 83 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION, CONCENTRATE / INTRAVENOUS | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GEL / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SUBCUTANEOUS | 28 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / TOPICAL | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAOCULAR | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRALESIONAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | POWDER, FOR SUSPENSION / ORAL | 19 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CONCENTRATE / ORAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SPRAY, METERED / NASAL | 0.06 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | LOTION / TOPICAL | 0.2 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / RESPIRATORY (INHALATION) | 8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE / ORAL | 238 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | PASTE / ORAL | 48 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET / ORAL | 6 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7df0a51f-ea79-754b-e053-2991aa0a5e6c | babcbe50-05c2-45d7-a1f5-07f65bbb45e8 | 2018-12-26 | Warnings | 7df0a51f-ea79-754b-e053-2991aa0a5e6c babcbe50-05c2-45d7-a1f5-07f65bbb45e8 |
Adverse event summaries are temporarily unavailable. Other product information remains available.